IgE
EstablishedIgE is central to allergy diagnosis and directly determines dosing eligibility for the biologic drug omalizumab.
IgE drives allergic reactions, and its level in the blood determines dosing for a major asthma biologic drug. A real gap exists though: many patients with severe asthma have IgE levels higher than the official dosing charts cover, even though evidence suggests the drug still helps them.
Immunoglobulin E (IgE) mediates allergic and anti-parasitic immune responses; total and allergen-specific IgE testing is central to diagnosing and managing allergic disease, including severe asthma.
Elevated total IgE supports an allergic/atopic phenotype and, in severe asthma, determines eligibility for omalizumab, an anti-IgE biologic; allergen-specific IgE identifies particular triggers (foods, pollens, medications).
Measured via serum immunoassay; omalizumab dosing is calculated directly from baseline IgE level and body weight using manufacturer dosing tables.
A real access gap exists: official omalizumab dosing tables only cover patients up to 1,500 IU/mL (EU) or 700 IU/mL (US), while many severe asthma patients have higher levels, leaving them technically outside labeled dosing guidance despite growing off-label evidence supporting treatment anyway.
A real treatment-access gap exists for patients with IgE levels above current official dosing table limits.
- PMC. (2023). Omalizumab for the treatment of patients with severe allergic asthma with IgE levels above >1500 IU/mL.